• Dyne Therapeutics Inc DYN.OQ reported a quarterly adjusted loss of 96 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -99 cents. The mean expectation of ten analysts for the quarter was for a loss of 71 cents per share. Wall Street expected results to range from -80 cents to -61 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Dyne Therapeutics Inc's reported EPS for the quarter was a loss of 96 cents​.

• The company reported a quarterly loss of $97.13 million.

• Dyne Therapeutics Inc shares had fallen by 21.7% this quarter and gained 111.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Dyne Therapeutics Inc is 52.50

This summary was machine generated from LSEG data November 12 at 03:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)